Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters) - Amgen Inc's new osteoporosis drug denosumab delayed fractures and other bone problems in patients with advanced breast cancer five months longer than Novartis AG's Zometa, according to data from a large clinical trial.
CHAPEL HILL, N.C. (Reuters) - Elizabeth Edwards, a best-selling author and a driving force behind her husband John Edwards' political career before it was destroyed by his infidelity, died on Tuesday at age 61.
LONDON (Reuters) - Britain's healthcare cost agency NICE has rejected Roche's Avastin as a treatment for advanced breast cancer and given a poor assessment of the drug ahead of a decision soon on its status in the key U.S. market.
NEW YORK (Reuters Health) - Breast cancer survivors who struggle with hot flashes may find respite in an antidepressant, according to a new study that suggests the medication should be the go-to drug when the overheating is severe.
ZURICH (Reuters) - European healthcare regulators are reviewing the benefits of Roche's top-selling Avastin drug in breast cancer in the light of fresh clinical data, casting more uncertainty over its prospects.
Lapatinib plus Trastuzumab was more effective than Lapatinib alone for women with HER2 positive advanced breast cancer that progressed on trastuzumab, San Antonio study shows.
Four studies presented at the San Antonio Breast Cancer Symposium looked at existing therapies being tested in unique ways as the landscape of acceptable treatment and management of breast cancer continues to shift.
Single-agent chemotherapy is recommended over combination for metastatic disease, says the European School of Oncology’s Metastatic Breast Cancer Task Force.
We encourage you to join the efforts of our friends at the Metastatic Breast Cancer Network to declare October 13 National Metastatic Breast Cancer Awareness Day.
Olaparib, a PARP inhibitor pill, worked powerfully against BRCA-related metastatic breast cancers, an American Society of Clinical Oncology (ASCO) study showed.